CONMED (NYSE:CNMD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Key Points

• JPMorgan raised CONMED’s price target from $45 to $50 while maintaining a “neutral” rating, implying approximately 9.8% upside from the prior close.
• Analyst sentiment remains cautious overall: CONMED has an average “Reduce” rating and a consensus price target of $44, with seven Hold ratings and one Sell rating.
• CONMED exceeded quarterly EPS expectations at $1.04 versus $1.00, but revenue fell 0.7% year over year to $335.56 million and EPS declined from $1.08 in the prior-year quarter.

CONMED (NYSE:CNMD - Get Free Report) had its target price hoisted by research analysts at JPMorgan Chase & Co. from $45.00 to $50.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s price target suggests a potential upside of 9.80% from the stock's previous close.

A number of other brokerages have also weighed in on CNMD. Piper Sandler reaffirmed a "neutral" rating and issued a $45.00 price objective (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. Zacks Research raised CONMED from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Wells Fargo & Company raised their price target on CONMED from $46.00 to $49.00 and gave the company an "equal weight" rating in a report on Thursday. Weiss Ratings upgraded CONMED from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, October 21st. Finally, Wall Street Zen raised CONMED from a "hold" rating to a "buy" rating in a report on Monday, July 20th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Reduce" and an average price target of $44.00.

CONMED Stock Performance

NYSE CNMD traded down $0.22 during trading on Thursday, reaching $45.54. The company's stock had a trading volume of 482,035 shares, compared to its average volume of 506,536. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.69 and a current ratio of 1.48. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 2.25 and a beta of 0.94. CONMED has a twelve month low of $31.44 and a twelve month high of $53.66. The business's fifty day moving average price is $47.32 and its 200-day moving average price is $41.43.

CONMED (NYSE:CNMD - Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.04. CONMED had a net margin of 4.12% and a return on equity of 14.31%. The business had revenue of $335.56 million during the quarter, compared to the consensus estimate of $336.28 million. During the same quarter in the prior year, the firm earned $1.08 earnings per share. The business's quarterly revenue was down .7% compared to the same quarter last year. As a group, analysts anticipate that CONMED will post 4.54 EPS for the current fiscal year.

Hedge Funds Weigh In On CONMED

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Signaturefd LLC boosted its holdings in shares of CONMED by 82.7% during the third quarter. Signaturefd LLC now owns 548 shares of the company's stock valued at $25,000 after acquiring an additional 248 shares during the period. Public Employees Retirement System of Ohio acquired a new position in CONMED during the 2nd quarter worth $27,000. Rockefeller Capital Management L.P. increased its holdings in shares of CONMED by 48.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,043 shares of the company's stock valued at $42,000 after purchasing an additional 341 shares during the period. Versant Capital Management Inc increased its holdings in shares of CONMED by 210.8% during the second quarter. Versant Capital Management Inc now owns 1,125 shares of the company's stock valued at $37,000 after purchasing an additional 763 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of CONMED during the second quarter valued at about $41,000.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED earned $1.04 per share, exceeding the analyst consensus of $1.00. The company also reported that third-quarter profit increased and updated its 2026 outlook. CONMED Q3 Profit Rises, Updates 2026 Guidance
• Positive Sentiment: Wells Fargo raised its price target for CONMED from $46 to $49 while maintaining an “equal weight” rating. The higher target suggests analysts see some upside, although the unchanged rating signals limited conviction. Wells Fargo CONMED Rating
• Neutral Sentiment: Third-quarter revenue of $335.56 million was broadly in line with expectations of $336.28 million. Management’s earnings call and results release provide additional detail on the company’s operating performance and 2026 guidance. CONMED Third-Quarter 2026 Financial Results
• Negative Sentiment: Revenue declined approximately 0.7% year over year, while EPS fell from $1.08 in the same quarter last year to $1.04. This indicates that the earnings beat was driven against expectations rather than underlying year-over-year growth. CONMED Q3 Earnings Top Estimates

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company's orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.